

Ayuda Ideas Semilla AECC 2023

Adjudicatarios

<p>Dra. Samanta Romina Zanetti Centro de Investigación Cooperativa en Biociencias (CIC Biogune)</p>	<p>IL411 is a promising therapeutic target to overcome resistance to CAR-T cell therapy in lung cancer</p>
<p>Dra. Teresa Guillamón Instituto de Neurociencias de Alicante (UMH-CSIC)</p>	<p>Astrocytic and neuronal calcium dynamics as predictors of brain cancer progression</p>
<p>Dra. Edurne Rujas Universidad del País Vasco (UPV/EHU)</p>	<p>In vivo evaluation of the stability and pharmacokinetic profile of the "Backpacked-antibody" platform for cancer immunotherapy</p>
<p>Dra. Lara García Instituto de Investigación Sanitaria de Santiago (IDIS)</p>	<p>Early molecular diagnosis of glioblastoma using Immuno-PET imaging with bispecific antibodies</p>
<p>Dr. Rubén García Centro Nacional de Biotecnología (CNB-CSIC)</p>	<p>Using novel microRNA sorting EXO- and CELL-motifs to prevent tumor growth</p>
<p>Dr. Sergio Granados Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO)</p>	<p>Proof-of-concept for a new bimodal cancer nanovaccine to potentiate immunotherapy</p>
<p>Dra. Aida Ninerola Fundació Clínic per a la Recerca Biomèdica-IDIBAPS</p>	<p>Remote assistance for radio-guided surgery in a mixed reality environment</p>

Suplentes

Dr. Roger Bresoli Universidad Ramón Llull (URL)	Clustering-Triggered Emission Materials: proof of concept for alternative anticancer photodynamic therapy (CTE-PDT)
Dr. Pablo Sarobe Cancer Center Clínica Universidad de Navarra (CIMA-CCUN)	CD40L as a marker to identify dominant CD8 tumor neoantigen epitopes for vaccination
Dr. Alfredo Martínez Centro de Investigación Biomédica de La Rioja (CIBIR)	Creating a platform to repurpose current drugs to target cancer nanotubes and mitochondrial hijacking (Immunotherapy 2.0)